Concizumab (Biosimilar Reference Antibody) (TFPI)
Concizumab (Biosimilar Reference Antibody) (TFPI)
Concizumab (Biosimilar Reference Antibody) (TFPI)-RA0713-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
ELISA plate pre-coated Antigen protein, can bind Concizumab (Biosimilar Reference Antibody) (TFPI)-RA0713 in a linear range of 3.91-125 ng/mL.
Concizumab (Biosimilar Reference Antibody) (TFPI)

Catalog: 

RA0713

Target

TFPI

Isotype

IgG4 - kappa

Applications

ELISA;FC;Functional Assays;IF

Reactivities

Human

Size (＄)：

100 μg-50;1 mg-210;5 mg-500;10 mg-800;25 mg-1750;50 mg-3000;100 mg-4600

Data Sheet

Material Safety Data Sheet

Certificate of Analysis

Product Description

Concizumab is an investigational humanized monoclonal antibody developed as a novel prophylactic treatment for hemophilia A and B, regardless of inhibitor status. It represents a new class of therapy known as an anti-TFPI (tissue factor pathway inhibitor) antibody. Unlike traditional factor replacement therapies, concizumab works by modulating the body's own natural coagulation pathway to enhance thrombin generation. It is administered via subcutaneous injection, offering a significant convenience advantage over intravenous factor products. Clinical trials have demonstrated its potential to reduce bleeding episodes effectively.

Synonyms

Anti-TFPI, mab2021, NN7415, concizumab-mtci

CAS

1312299-39-0

Isotype

IgG4 - kappa

Host

Humanised

Target

TFPI

Reactivity

Human

Expression System

CHO

Applications

ELISA, FC, Functional Assays, IF; Recommended dilution: FC, IF:1:200

Purity

>98% by SDS-PAGE

Concentration

Bottled at the concentration indicated on the vial.

Buffer

0.01M PBS, pH 7.4, contains no stabilizers or preservatives.

Endotoxin

<1.0 EU/mg as determined by LAL method

Conjugation

Non-conjugated

Formulation

Liquid or Lyophilized powder Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

store at -20°C or -80°C. Avoid repeated freeze.

Type

Antibody

Purposes

For research use only

References 1

Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696.

References 2

Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9.

References 3

References 4

References 5

Product Citations 1

Product Citations 2

https://pubmed.ncbi.nlm.nih.gov/33819375/
https://pubmed.ncbi.nlm.nih.gov/24568891/
https://www.oursmab.com/News/Tissue-factor-pathway-inhibitor-TFPI.html

Target Description

Synonyms

tissue factor pathway inhibitor, extrinsic pathway inhibitor, EPI, lipoprotein-associated coagulation inhibitor, LACI

Biology Area

Metabolism;Hematology

Function

Tissue factor pathway inhibitor (TFPI), specifically its Kunitz-type protease inhibitor 2 (KPI-2) domain. TFPI is a natural anticoagulant protein that plays a crucial role in regulating the initiation phase of blood coagulation (the extrinsic pathway). It functions by inhibiting the tissue factor/factor VIIa (TF/FVIIa) complex and factor Xa. In hemophilia, the deficiency of factor VIII or IX creates a fragile clot, and the inhibitory activity of TFPI further suppresses the already weakened coagulation cascade.

Additional Articles 1

Tissue-factor-pathway-inhibitor-TFPI

Additional Articles 2

Related Products

Atoltivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0713

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Tocilizumab (Biosimilar Reference Antibody) (IL6R)

Catalog: 

RA0713

Target：

IL6R/CD126

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Cosfroviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0713

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Bempikibart (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0713

Target：

IL7R/CD127

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Maftivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0713

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Lusvertikimab (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0713

Target：

IL7R/CD127

Isotype：

IgG4 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Odesivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0713

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Porgaviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0713

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Enokizumab (Biosimilar Reference Antibody) (IL9)

Catalog: 

RA0713

Target：

IL9

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Bapotulimab (Biosimilar Reference Antibody) (ILDR2)

Catalog: 

RA0713

Target：

ILDR2

Isotype：

IgG2 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human

Contact Us

Send your request

Talk to us 

Get a quotation, discuss your requirement, receive advises from our antibody experts without obligation.